Dyadic International (NASDAQ:DYAI) Posts Earnings Results, Misses Expectations By $0.01 EPS

Dyadic International (NASDAQ:DYAI) posted its quarterly earnings data on Wednesday. The biotechnology company reported ($0.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01), Zacks reports. Dyadic International had a negative return on equity of 149.16% and a negative net margin of 188.09%. The company had revenue of $0.82 million for the quarter, compared to analyst estimates of $1.60 million. During the same quarter in the prior year, the company posted ($0.24) earnings per share.

Dyadic International Stock Performance

NASDAQ DYAI opened at $1.33 on Thursday. The company has a debt-to-equity ratio of 1.54, a current ratio of 5.15 and a quick ratio of 5.15. The stock’s 50 day simple moving average is $1.48 and its 200-day simple moving average is $1.42. The company has a market cap of $39.35 million, a PE ratio of -5.78 and a beta of 0.95. Dyadic International has a 1-year low of $0.93 and a 1-year high of $2.67.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Dyadic International stock. Bank of America Corp DE lifted its stake in shares of Dyadic International, Inc. (NASDAQ:DYAI) by 16,146.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 27,132 shares of the biotechnology company’s stock after purchasing an additional 26,965 shares during the period. Bank of America Corp DE owned 0.09% of Dyadic International worth $47,000 as of its most recent SEC filing. Institutional investors own 27.95% of the company’s stock.

Dyadic International Company Profile

Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.